LLY Jun 2024 200.000 call
| Previous close | 271.25 |
| Open | 271.25 |
| Bid | 252.75 |
| Ask | 255.60 |
| Strike | 200.00 |
| Expiry date | 2024-06-21 |
| Day's range | 271.25 - 271.25 |
| Contract range | N/A |
| Volume | |
| Open interest | 14 |
- Yahoo Finance Video
Why these analysts are bullish on healthcare stocks
The healthcare sector has underperformed throughout 2024, but as the first quarter earnings season unfolds, Jefferies Healthcare Services Equity Research Analyst Brian Tanquilut and Grey Ghost Advisors Private Equity Investor Meghan Fitzgerald join Market Domination to discuss how investors should position themselves in this market. Fitzgerald remains bullish on the healthcare sector, believing it still has "a lot of long and important tailwinds." She cites the sector's historical outperformance during market downturns and election years as reasons for her optimism. Fitzgerald anticipates strong earnings from companies with GLP-1 drug portfolios this week, describing it as an "easy beat." Tanquilut notes a "rise in broader healthcare utilization trends," which is now reflected in healthcare insurers' earnings. While there has been weakness in this area, he highlights the "strength in volume" from healthcare providers. However, Tanquilut acknowledges that with consumer spending slowing, consumer-focused healthcare segments, such as drugstores, have experienced pressure. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. Editor's note: This article was written by Angel Smith
Yahoo FinanceHow expanded use of GLP-1s could affect long-term outlooks for Eli Lilly and Novo Nordisk
The latest GLP-1 drugs are starting to see proof of greater use beyond diabetes and obesity. How will it affect makers Novo Nordisk and Eli Lilly?
ReutersEli Lilly lifts profit view amid strong demand for diabetes and weight-loss drugs
Sky-rocketing demand for Mounjaro and Zepbound, both chemically known as tirzepatide, has propelled the drugmaker's market value above $700 billion - surpassing that of Tesla and Walmart. In the short- to mid-term, the U.S. drugmaker expects sales growth for its weight-loss and diabetes treatments to primarily be a function of quantity that it can produce and ship. Danish drugmaker Novo Nordisk, which manufactures the weight-loss drug Wegovy and related diabetes treatment Ozempic, is Lilly's main rival in the obesity market.
